691 / 1138
Chang J, Senan S, Lancet Oncol 2015
Estimated 3-year OS was
95%
(95% CI 85-100) for SABR vs.
79%
(64-97) for surgery
3-year recurrence-free survival of
86%
(95% CI 74-100) in SABR
group vs.
80%
(65-97) in surgery
group (HR 0.69, 95% CI
0.21-2.29, log-rank
P
=0.54)